Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis

Clinical Endocrinology

Volumn 79, Issue 4, 2013, Pages 499-503

  Makras, Polyzois ^a   Polyzos, Stergios A ^b   Papatheodorou, Athanasios ^a   Kokkoris, Panagiotis ^a   Chatzifotiadis, Daniel ^a   Anastasilakis, Athanasios D ^c  

^a IASO GENERAL HOSPITAL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c 424 General Army Hospital   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CALCIUM; CALCIUM CARBONATE; CARBOXY TERMINAL TELOPEPTIDE; COLECALCIFEROL; COLLAGEN TYPE 1; DENOSUMAB; PARATHYROID HORMONE;

ADULT; ARTICLE; BODY MASS; BONE DENSITY; CLINICAL ARTICLE; FEMALE; FEMUR NECK; HUMAN; LUMBAR SPINE; MULTICENTER STUDY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; VITAMIN SUPPLEMENTATION;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY; CALCIUM; CALCIUM CARBONATE; CHOLECALCIFEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VITAMINS;

EID: 84883531785     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12188     Document Type: Article

References (12)

1. Anastasilakis, A.D., Toulis, K.A., Polyzos, S.A., et al,. (2012) Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab. Therapeutics and Clinical Risk Management, 8, 295-306.
2. Pierroz, D.D., Bonnet, N., Baldock, P.A., et al,. (2010) Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL. Journal of Biological Chemistry, 285, 28164-28173.
3. Bekker, P.J., Holloway, D.L., Rasmussen, A.S., et al,. (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. Journal of Bone and Mineral Research, 19, 1059-1066.
4. Cummings, S.R., San, M.J., McClung, M.R., et al,. (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. New England Journal of Medicine, 361, 756-765.
5. Seeman, E., Delmas, P.D., Hanley, D.A., et al,. (2010) Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. Journal of Bone and Mineral Research, 25, 1886-1894.
6. Seeman, E., Libanati, C., &, Austin, M., et al,. (2011) The Transitory increase in PTH Following Denosumab Administration is Associated with Reduced Intracortical Porosity: a Dinstictive Attribute of Denosumab Therapy. Journal of Bone and Mineral Research, 26 (Suppl 1), S1. Available at http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid= 51d4e88b-f79d-47e2-a15b-134f0c57b52e. Accessed November 17, 2011.?aid=51d4e88b- f79d-47e2-a15b-134f0c57b52e. Accessed November 17, 2011.
7. Makras, P., &, Papapoulos, S.E., (2009) Medical treatment of hypercalcaemia. Hormones (Athens), 8, 83-95.
8. Eastell, R., Christiansen, C., Grauer, A., et al,. (2011) Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. Journal of Bone and Mineral Research, 26, 530-537.
9. Papapoulos, S., Chapurlat, R., Libanati, C., et al,. (2012) Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. Journal of Bone and Mineral Research, 27, 694-701.
10. Leder, B., Uihlein, A., &, Neer, R., et al,. (2012) The effects of combined Denosumab and Teriparatide administration on bone mineral density in postmenopausal women: the DATA (Denosumab And Teriparatide Administration) Study. Journal of Bone and Mineral Research, 27 (Suppl 1), S1. Available at http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid= 51d4e88b-f79d-47e2-a15b-134f0c57b52e. Accessed November 17, 2012.
11. Cosman, F., Eriksen, E.F., Recknor, C., et al,. (2011) Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. Journal of Bone and Mineral Research, 26, 503-511.
12. Bolland, M.J., Grey, A., Avenell, A., et al,. (2011) Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ, 19 (342), d2040.